Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cytarabine

Criteria

Inclusion Criteria:

• Newly diagnosed patient.

• Provision of written informed consent.

• De Novo (primary) or Secondary AML.

• Not eligible for intensive induction chemotherapy because of medical, social or psychological reasons.

Exclusion Criteria:

• Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL).

• Patients with blast crisis of chronic myeloid leukaemia.

• Persistent, chronic, clinically significant toxicities from any prior anti- cancer therapy greater than CTCAE Grade 1 (except alopecia).